Back to Search
Start Over
Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body Myositis
- Source :
- Business Wire. November 13, 2023
- Publication Year :
- 2023
-
Abstract
- NEWTON, Mass. -- Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Business Wire
- Publication Type :
- News
- Accession number :
- edsgcl.772559833